Leading scientists in the field of cystic fibrosis research are in Cork today to evaluate the findings of CFMATTERS - an Irish-led, €6 million EU-funded study into the effectiveness of  using new DNA-based technologies to treat the disease.

There are 1,200 cystic fibrosis patients in Ireland which has the highest incidence (per head of population) of cystic fibrosis in the world.

The project is the first randomised, controlled trial comparing the use of microbiome-directed antibiotic treatment to the standard therapy for CF patients which has been in use for decades.

Led by Professor Barry Plant of Cork University Hospital, the study has been following 227 patients from nine clinical sites in Ireland, UK, Europe and the USA over a three year period.